Overview
GHRH analog modified with DAC (Drug Affinity Complex). DAC modification extends half-life to approximately 8 days, enabling dosing 1-2 times per week.
| Chemical Class | GHRH analogues (long-acting) |
| Specification | 2mg/stick |
| Dosing Frequency | 1-2 times a week |
| Storage | Refrigerate at 2-8°C |
Mechanism of Action
GHRH receptor activation: same as CJC-1295
DAC albumin binding: prolonged residence time in the body
Long-lasting release: continuously stimulates GH secretion
Related to indications: long-acting version, low dosing frequency, suitable for long-term programs.
| Indication | Mechanism | Evidence |
|---|
| GH secretion support | GHRH long-lasting activation | experimental research |
Dosage & Administration
Safety Information
Regulatory Status
Explanation of missing informationLack of clear regulatory status information. It is recommended to check the FDA Orange Book, NMPA Drug Evaluation Center, and WADA banned list.
Drug Interactions
FAQ
Q1: How long will it take to see changes?
The change time varies greatly depending on the product mechanism and personal physique. It is recommended to refer to clinical trial data of similar products.
Q2: Will it rebound after deactivation?
Depends on product category and individual maintenance regimen. Metabolic products may gradually return to baseline; repair products are usually long-lasting.
Q3: Can it be used with other supplements?
In most cases, it is possible, but care should be taken to avoid overlapping products with the same mechanism. Please refer to Module 13 ‘Drug Interactions’ for details.
Q4: Why is it banned for athletes?
Some products are included in WADA’s banned list. Athletes should check the latest WADA list before use.
Q5: What is the difference from XX products?
Please see the competitor comparison matrix for this category.
Q6: Are there any side effects?
Please see Module 12 ‘Safety and Toxicology Details’.
Q7: Does it need to be used for a long time?
Depends on product category and target. Please refer to Module 10 ‘Dosage and Administration’ for treatment recommendations.
Q8: Who is not suitable?
Please refer to Module 8 ‘Contraindications and Precautions’.
Q7: Does it need to be used for a long time?
Depends on product category and target. Please refer to Module 10 ‘Dosage and Administration’ for treatment recommendations.
Q8: Who is not suitable?
Please refer to Module 8 ‘Contraindications and Precautions’.
Disclaimer: This product is intended for research purposes only. Not for human consumption or therapeutic use. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
